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There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions.
Pathophysiologically, HF is defined as the inability of the heart to provide adequate perfusion to the body and its tissues. Clinically, HF is defined as a syndrome with typical signs (pulmonary congestion, peripheral edema, and elevated jugular venous pressure) and symptoms (dyspnea, ankle swelling, and fatigue), which result from abnormal cardiac structure or function. 1, 2 HF is a highly prevalent disease, affecting 5.8 million people in the USA and nearly 15 million in Europe. 3, 4 The symptoms and the need for frequent hospitalizations in HF cause a significant burden on individual patients. At the same time, HF is a major public health concern due to the need for frequent and intense healthcare resource utilization. 1, 2, 4, 5 Further, despite the use of currently available therapies, the prognosis of patients with HF is considerably poor, with 5-year survival rates of 50%, a prognosis even worse than that of patients with advanced cancer or stroke. 6 In HF, echocardiography has traditionally been used to quantify left ventricular ejection fraction (EF; derived as stroke volume/end-diastolic volume) which is then used to define two types of patient populations: patients with HF and reduced EF (HFrEF) and those with HF and preserved EF (HFpEF). The distinction is not only important because EF constitutes an important prognostic factor, but also because patients with HFpEF seem to respond differently to available therapies than patients with HFrEF. 7, 8 Currently, there are no approved drugs for treatment of HFpEF. All major trials on new drugs in patients with HF were conducted in patients with HFrEF (mainly EF 35%).
1,2 For the purpose of this review, the authors focused on the chronic HFrEF population. Our review aims to define a set of criteria and parameters that can be used to support Go/NoGo decisions during early clinical development of new molecular entities (NME) for chronic HFrEF. We aimed to identify factors with a positive predictive value for early development by analyzing clinical parameters and biomarkers during the initial phase of the development for NMEs that achieved a clinical benefit (usually morbidity and mortality) during their confirmatory part of drug development. As the potential HF treatments are directed towards specific therapeutic targets right from the beginning, the traditional and often-used pathway to expand a proven cardiovascular therapy approved for an existing indication (e.g., hypertension) is not covered in this review. Further, it is well understood that encouraging early clinical, functional and biomarker data supporting a Go decision are followed by investigation of the dose-response of beneficial effects and the compatibility with other state-of-the-art HF therapies and constitute an equally important next milestone. [9] [10] [11] CURRENT PHARMACOTHERAPY FOR HEART FAILURE The goals of treatment in patients with HF are to improve signs and symptoms and quality of life (QoL), prevent hospital readmissions, and reduce mortality rates. For the technical success of new drugs (regulatory approval) as well as the commercial success of a compound, evidence of reduction of mortality is unquestionably the most desirable objective.
Current pharmacotherapy for HFrEF mainly includes drugs that modify (or at least attenuate) the disease process and prolong survival, and those that only ameliorate the clinical signs and symptoms of HF. The first group of drugs that are guidelinerecommended treatments with consistently proven long-term benefits 12 include 1) blockers of the renin-angiotensinaldosterone system (RAAS) such as angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor type 1 (AT1) antagonists (ARBs), and mineralocorticoid receptor antagonists (MRAs); 2) blockers of the adrenergic system, namely, beta adrenoceptor blockers (BBs); 3) the angiotensin receptor-neprilysin inhibitor (ARNI); and 4) hydralazine and isosorbide dinitrate (in self-identified African-American patients or in those intolerant to ACEI and ARB). Sacubitril/valsartan (previously known as LCZ696), the first-in-class ARNI, simultaneously inhibits neprilysin, an enzyme responsible for degradation of several vasoactive peptides including natriuretic peptides, and blocks the AT1 receptor. It is the most recent addition to the armamentarium of HFrEF drugs and was more effective than enalapril in reducing morbidity and mortality in patients with HFrEF in the PARADIGM-HF trial. 13 Other drugs such as diuretics, digoxin, and nitrates are used for symptomatic relief in patients with HFrEF without any demonstrated mortality benefit. 1 An overview of established therapies in HFrEF is presented in Table 1 .
EVOLUTION OF PATHOPHYSIOLOGICAL CONCEPTS IN HEART FAILURE AND NEW THERAPEUTIC STRATEGIES
In the 1980s, HFrEF was considered primarily a hemodynamic disorder, and therapeutic interventions that acutely improved pump function were believed to provide long-term clinical benefit. Therefore, the therapeutic goal was to increase cardiac output (CO) by either increasing contractility or reducing peripheral resistance using vasodilators.
14 This concept was questioned when a number of controlled clinical trials conducted in the 1990s showed that drugs that improved hemodynamics did not necessarily show long-term clinical benefits with regard to reduction in mortality. 15, 16 These observations and the dramatic clinical effects with ACEIs and BBs in large interventional studies caused a paradigm shift in the pathophysiological concepts of HFrEF. [17] [18] [19] [20] Until recently, blockers of the neurohormonal systems (RAAS and adrenergic system) were considered the most effective therapeutic options. 2 Data from the recently completed PARADIGM-HF study comparing sacubitril/valsartan with enalapril provided evidence that in addition to blocking the detrimental effects related to sustained RAAS activation, inhibition of neprilysin and subsequent enhancement of beneficial effects of vasoactive peptides further reduced morbidity and mortality in patients with HFrEF. 13 An overview of therapeutic principles tested as potentially new medicines for HFrEF are presented in Table 2 . Despite encouraging primary pharmacology data and pathophysiological fit, research on these therapeutic principles had to be discontinued, or their use restricted to the symptomatic management of patients with acute HF because of the lack of efficacy or safety concerns. Drugs currently being evaluated in ongoing studies have been discussed elsewhere and are not part of this review. 21 
IMPLICATIONS OF MORTALITY AS THE PRIMARY REGISTRATION ENDPOINT
As HFrEF is a life-threatening disease, mortality is regarded as the most important single endpoint in phase III studies for evaluation of new drugs for HF. Drugs with other beneficial effects might be approved by regulatory authorities but only under the condition that excess mortality can be excluded. In these cases, mortality (usually all-cause mortality) helps to assess the drug's safety profile.
Although mortality is an important and easily measurable endpoint, it has several limitations. The main concern of using only mortality as an endpoint in clinical trials is that it refers to the terminal manifestation of HFrEF. Thus, in an outcome study many patients may not contribute to the mortality endpoint, but may have a significantly impaired QoL. Further, the current management of HFrEF with ACEIs/ARBs, BBs, and MRAs has reduced mortality considerably.
1,2 Therefore, if mortality is the primary endpoint, patients with advanced disease have to be enrolled in trials to accrue enough mortality events to provide adequate statistical power within a reasonable period of time. The need to demonstrate a mortality benefit makes it difficult to validate the benefit of a new medication in patients with less pronounced HFrEF or in those with severe HF. Finally, trials in which mortality is the primary endpoint require a large sample size to show a survival benefit of a new drug. Therefore, to evaluate preventative strategies using mortality as an endpoint, large and long-term phase III clinical trials are needed. Parameters, indices, or biomarkers that are indicative of the potential safety, morbidity, and mortality benefits (or the lack of it) of a new drug have emerged as valuable tools. Such biomarkers are increasingly being recognized as endpoints during the early stages of clinical development (phase I/II) to critically evaluate the developmental path of a new drug.
BIOMARKERS, CLINICAL ENDPOINTS, AND SCORES IN HEART FAILURE
Heerspink et al. 22 recently suggested the parameter response efficacy (PRE) score that reflects potential long-term cardiovascular (CV) or renal benefits and risks and can be used to assess new drugs for a broad range of CV indications. To date, the most frequently used scores for the clinical assessment of the disease stage of patients with HFrEF include the New York Heart Association (NYHA) classification that reflects severity of symptoms and exercise intolerance as assessed by the physician, the Minnesota Living with Heart Failure Questionnaire (MLHFQ), and the Kansas City Cardiomyopathy Questionnaire (KCCQ) that represents how the patient feels. 2, 23, 24 Past research has focused on more objective, sensitive, and better quantifiable parameters of disease severity and prognosis. Presently, the spectrum of available measures includes:
Hemodynamic factors: blood pressure (BP), heart rate (HR), cardiac output (CO), systemic vascular resistance (SVR), and pulmonary capillary wedge pressure (PCWP). Autonomic nervous system markers: heart rate variability, baroreceptor sensitivity, and ventricular repolarization characteristics (QT-dispersion). Exercise capacity: 6-min walk test, treadmill or cycle exercise testing, and spiroergometry. Soluble biomarkers/neurohormones: norepinephrine, epinephrine, and natriuretic peptides (atrial and brain natriuretic peptides) and high-sensitivity troponin.
Cardiac imaging indices: left ventricular EF (LVEF) and left ventricular end-systolic and end-diastolic pressures (LVESP and LVEDP).
The majority of the parameters and markers mentioned above have been used for clinical purposes spanning from the confirmation of diagnosis of (clinically asymptomatic) HF to the classification of the patients' clinical status and assessment of prognosis. Despite the large number of parameters and indices available, none of them fulfill the hard criteria of a real surrogate, i.e., a biomarker that can replace or predict a real clinical endpoint. 25 Nevertheless, experience from previous clinical trials provide useful and relevant information on these markers and their use for early drug development. Three examples may illustrate the value of these markers: 1) LVEF: Changes in LVEF >5% from baseline at 6 months (V-HeFT I) and 12 months (V-HEFT II) were found to be strong predictors of mortality. 26 No contradictory observations have been published so far. 2) Hemodynamics: All drugs approved for the treatment of HF have long-term beneficial hemodynamic effects. Nevertheless, a number of controlled clinical trials conducted in the 1990s have shown that drugs that produce striking hemodynamic benefits do not necessarily produce long-term clinical benefits. 15, 16 These findings discouraged the use of hemodynamic variables as surrogate markers for predicting drug efficacy. However, the converse is not true: there are no drugs that worsen hemodynamics and improve long-term outcomes.
3) Six-minute walk test: Although the 6-min walk test was found to predict long-term mortality and hospitalization rates in patients with left ventricular dysfunction of varying causes and severity, 27 other researchers could not confirm these findings. 28 Based on the predictive value, these markers can be classified in two categories: 1) those that have positive predictive value ("positive parameter or index"), i.e., a positive/beneficial effect can be inferred from them (indicating potential Go criteria), and 2) those that have a negative predictive value (providing potential NoGo criteria), i.e., an effect on this marker would suggest detrimental effects in humans. It is noteworthy that some parameters or indices (such as hemodynamics, CO, PCWP) that are strong predictors of mortality are not good at predicting therapeutic response.
The value and limitations of parameters or indices for doserange finding, target engagement, clinical proof of concept, and decision-making regarding further clinical development have been extensively discussed in the literature. 25, 29 Based on general and HFrEF-specific knowledge on biomarkers, parameters, or indices, it can be concluded that early drug development in HFrEF should focus on ruling out valid NoGo criteria and confirming target engagement and proof of concept. Therefore, we propose an approach that includes defining NoGo criteria that must be ruled out to justify further progression of clinical development, and assessing predictive biomarkers to estimate potential clinical benefits. Figures 1 and 2 illustrate two theoretical outcomes of an early clinical development program. The figures demonstrate that even in the case of evidence of positive pharmacodynamic effects of a drug candidate, the fact that one NoGo criterion has been met may question the whole therapeutic approach and result in discontinuing further clinical development.
IMPLEMENTATION OF EXPLORATORY CLINICAL DEVELOPMENT PRINCIPLES
Considering the complexity, large size, long treatment duration, and substantial costs of registrational clinical trials assessing morbidity and mortality in patients with HFrEF, 13, 30 it is evident that smaller studies are required at earlier development stages to enable well-informed decisions to either continue development of the new drug or to abandon the program. Due to the smaller size of these early trials, it is not possible to examine the hard endpoints of the registrational trials like morbidity and mortality. Instead, smaller trials will need to look at several markers as indicators of potential efficacy (Go criteria) as well as markers that are indicators of potentially deleterious effects (NoGo criteria). Blood pressure BP is a function of SVR and cardiac output An increase in BP contributes to an increased afterload on the ventricle that leads to adverse ventricular and vascular remodeling Many drugs for HF have anti-hypertensive properties (e.g., ACEIs, ARBs, BBs, diuretics, and nitrates) An increase in BP would be of concern BNP/NT-proBNP The biologically active natriuretic peptide BNP and its inactive precursor NT-proBNP are released upon increase in myocardial wall stress or stretch. BNP is eliminated by NEPmediated degradation and renal clearance; NT-proBNP is predominantly renally eliminated. Therefore, BNP needs to be interpreted with caution in patients treated with an angiotensin receptor-neprilysin inhibitor (ARNI; e.g., sacubitril/valsartan).
BNP/NT-proBNP are utilized to diagnose heart failure. BNP values at hospital admission for HF, at hospital discharge and serial changes have been shown to predict HF morbidity and mortality. In addition, guiding HF therapy according to BNP/NT-proBNP values is associated with lower cardiovascular events, in particular in elderly patients. Drugs that improve morbidity and mortality rates have been shown to reduce NT-proBNP levels Decrease in BNP by 25% and in NT-proBNP by 40% are considered to be biologically meaningful 61, 62 ARNI: Sacubitril/valsartan (NT-proBNP, change from In chronic heart failure, hs-TnT is detectable in more than 90% of patients, of whom 50% present with elevated hs-TnT indicative of ongoing myocardial injury 66, 76 Elevated levels of circulating hs- Proarrhythmic potential Sudden cardiac arrest is a leading cause of mortality in patients with HF A drug with proarrhythmic potential would be contraindicated in patients with HF who are at increased risk of sudden cardiac arrest Any evidence of proarrhythmic potential 54, 80 Plasma epinephrine One of two catecholamines (norepinephrine is the other one) that mediate the sympathetic nervous system
Increased plasma epinephrine levels are indicative of increased sympathetic activation that is maladaptive in patients with heart failure Any evidence of sympathetic nervous system activation ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BB, beta-blocker; BP, blood pressure; bpm, beats per minute; BNP, B-type natriuretic peptide; EF, ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; hs-TnT, high sensitivity troponin T; MRA, mineralocorticoid receptor antagonist; NEP, neutral endopeptidase/neprilysin; NT-proBNP, N-terminal pro B-type natriuretic peptide; OR, odds ratio; PCWP, pulmonary capillary wedge pressure; RAAS, renin-angiotensin aldosterone system; RCT, randomized controlled trial; RR, relative risk; SV, stroke volume; SVR, systemic vascular resistance.
The MOCHA study is an example of how assessments in a smaller trial of shorter duration can de-risk the decision to advance a drug candidate into full development. 31 In this 6-month study, carvedilol, the study drug, had no effect on the exercise tolerance test in 350 patients but improved left ventricular function and decreased mortality and hospitalization rates. However, Krum et al. 32 identified several beneficial effects with carvedilol therapy in a pilot study with 56 patients with severe HF. In this study all parameters, including symptom scores, functional parameters (6-min walk test), hemodynamics (stroke volume index, LVEF, pulmonary artery pressure, PCWP, right atrial pressure, and SVR), and preliminary major CV events were all in favor of the intervention.
Based on the above information, it becomes evident that during the early clinical program for development of HFrEF drugs, a number of critical assessments should be performed until a certain level of confidence can be attained that might justify undertaking a trial similar to the MOCHA trial. In general, however, it is important to note that successful drugs will not necessarily always meet all Go criteria but still be viable candidates for phase III development. In contrast, meeting any NoGo criteria clearly raises concerns on the overall benefit, safety, and utility of the therapeutic approach.
Currently, we can identify the following NoGo criteria that must be ruled out by a new drug candidate:
Increase in sympathetic tone, including HR and epinephrine levels. Activation (reflex) of the RAAS (increase in renin, angiotensin II, aldosterone), provided the mechanism of action of the drug candidate does not involve RAAS inhibition. Unfavorable effects on hemodynamic parameters (increase in LVEDP, PCWP, pulmonary vascular resistance, or decrease in CO). Adverse changes in cardiac structure and function and in biomarkers linked to deleterious cardiovascular effects.
Additional parameters or indices may suggest beneficial clinical effects and can help to determine the pharmacodynamically active doses for later clinical studies. These include a mid-to longterm increase in EF. 31, 32 Furthermore, circulating biomarkers such as natriuretic peptides, midregional pro-adrenomedullin (MRproADM), ST2, copeptin, galectin 3, and others have been studied for their value in diagnosing HFrEF, determining prognosis, and guiding therapy. However, only BNP, NT-proBNP, and hsTnT have been investigated convincingly in the context of drug development and are currently recommended to be evaluated early in a development program if a new drug candidate has the potential to modify clinically relevant endpoints such as mortality. 33 It should be noted, however, that neither of these biomarkers are validated surrogates. Based on the learnings summarized in Table  2 and the above considerations, we propose one set of criteria that might indicate future clinical success and another set that might be a signal for clinical safety concern. Table 3 provides an overview of these criteria and summarizes experience from previous drug development programs. These data allow the derivation of Go/NoGo criteria, which are summarized in Table 4 . Importantly, it is recommended to evaluate potential NoGo criteria related to unfavorable hemodynamic effects, sympathetic or neurohormonal activation, LV function, and proarrhythmic potential early on and as appropriate. If the drug candidate does not meet any potential NoGo criteria and is otherwise safe and well tolerated, evidence suggesting a favorable effect on pharmacodynamic endpoints will support a decision to progress a development program. Go criteria should be viewed in the context of the mode of action of the drug candidate, and Table 4 provides examples for potential criteria for which sufficient evidence was available in the literature. These criteria will need to be adapted to a specific compound under development (e.g., BNP as a neprilysin substrate should not be evaluated in the context of predicting response when neprilysin inhibitors are evaluated). The current literature does not support thresholds for Go or NoGo criteria for all biomarkers listed in Table 4 , and there are biomarker changes that can neither be attributed to the Go or NoGo category. The magnitude of the effect of the Go criteria will influence decisions to move ahead with a particular project. At the same time, the precise quantum of the change required to drive organizational decision-making will depend on the particular organization's setup, which includes, among other aspects, their R&D model and culture. Continuous evaluation of ongoing development programs may help to close some of these knowledge gaps in the future.
CONCLUSION
Based on current knowledge, we conclude that the exploratory clinical development of new drugs for HFrEF should be done with a balanced approach: a number of predefined NoGo criteria that should be ruled out, and a (smaller) number of parameters, indices, or biomarkers indicative of a clinical benefit (Go criteria) should be determined. With this approach, the transition of a clinical HFrEF project from one stage of development to the next is still associated with considerable development risk. However, individual decisions to expand from smaller and less predictive studies to larger, more costly, but more predictive studies will be based on clinical data and reflect the currently available development knowledge in HFrEF. Because of the complexity of the matter and the relatively large number of different effects that have to be proven and excluded, the implementation of these principles will have to be different for each individual drug candidate.
